Additionally and most importantly, after adopting CDK4/6 inhibitors in combination with AI as the standard first-line treatment for metastatic ER+ breast cancer a few years ago, newer clinical data have revealed minimal efficacy of fulvestrant monotherapy in the second line among these CDK4/6 inhibitor-treated tumors [21]. The gene discussed is CDK4; the disease is breast carcinoma.